| 0 (0%) | 08-14 20:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.38 |
1-year : | 7.45 |
| Resists | First : | 5.46 |
Second : | 6.38 |
| Pivot price | 4.79  |
|||
| Supports | First : | 3.99 |
Second : | 3.31 |
| MAs | MA(5) : | 5.54 |
MA(20) : | 4.66 |
| MA(100) : | 5.25 |
MA(250) : | 8.54 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 77 |
D(3) : | 90.4 |
| RSI | RSI(14): 55 |
|||
| 52-week | High : | 41.79 | Low : | 3.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ QNRX ] has closed below upper band by 37.4%. Bollinger Bands are 44.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.29 - 5.31 | 5.31 - 5.34 |
| Low: | 4.62 - 4.64 | 4.64 - 4.67 |
| Close: | 5.04 - 5.09 | 5.09 - 5.14 |
Fri, 14 Aug 2026
Quoin Q2 Loss Hits $5.37 Million as FDA Clears Peeling Skin IND - Quiver Quantitative
Fri, 14 Aug 2026
Quoin posts $5.4M Q2 net loss, $10.8M cash; advances QRX003 and QRX009 pipelines - TradingView
Fri, 14 Aug 2026
Quoin Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Fri, 14 Aug 2026
No approved treatment for Peeling Skin Syndrome as Quoin plans Phase 2/3 study - Stock Titan
Mon, 10 Aug 2026
Quoin Pharmaceuticals (QNRX.US) will release its earnings report before the market opens on August 14. - Moomoo
Mon, 10 Aug 2026
Quoin Pharmaceuticals Ltd (QNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 52.5 (%) |
| Shares Short | 156 (K) |
| Shares Short P.Month | 40 (K) |
| EPS | -10.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -76.2 % |
| Return on Equity (ttm) | -231.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -8.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.51 |
| PEG Ratio | 0 |
| Price to Book value | 1.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|